Seeking Alpha

Optimer Pharmaceuticals (OPTR) trades lower in the post-session after reporting a wider than...

Optimer Pharmaceuticals (OPTR) trades lower in the post-session after reporting a wider than expected Q3 loss. SG&A expenses jumped fourfold Y/Y to $26.9M, compared to $4.8M for the prior year, primarily due to its infrastructure build-up and marketing expenses related to the launch of its blockbuster drug DIFICID. Shares -7.8% AH.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs